CClinicalTrials.gg
TerminatedNCT03058393Updated Dec 17, 2019

Analyzing Challenging Clinical Discussions in Orthopaedics

An interventional study of Teach-Back Lesson in Teach-Back Communication, Arthritis and Knee Osteoarthritis, sponsored by Duke University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Duke University · Not applicable, Interventional, and Health services research

Why this study was terminated
Extenuating circumstances
Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The goal of this study is to analyze patient:provider communication surrounding the discussion of difficult clinical conversations such as knee replacement options. This study will also examine how using the teach-back communication technique can improve communication between patients and providers. Orthopedic residents, fellows, physician assistants, and attendings that agree to participate will be consented. Patients, who are likely to engage in a difficult clinical conversation, such as those who have a clinical indication for a Total Knee Replacement or a Partial Knee Replacement, will be recruited from participating providers clinical schedules. Patient:provider interactions will be recorded and then the providers will attend a 1 hour education lecture about how to use teach-back. After attending the lecture, additional patient:provider interactions will be recorded and analyzed via a qualitative approach. Additionally, providers will participate in a semi-structured interview to capture their perceptions of teach-back and what challenges and benefits they may derive from using it.

02

Conditions studied

  • Teach-Back Communication
  • Arthritis
  • Knee Osteoarthritis
  • Knee Arthropathy
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 7 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (Patient Participants):

  • Age 18 years and older
  • Clinical indication for multiple treatment options

Exclusion Criteria (Patient Participants):

  • Non-English speaking
  • Minors or non-consenting other individuals (spouses, friends, family members, children) in the patient room during the clinical visit

Inclusion Criteria (Provider Participants)

  • Age 18 years and older
  • A resident, fellow, physician assistant, or attending in the Duke Department of Orthopaedic Surgery

Exclusion criterion (Provider Participants):

  • Non-English speaking
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Teach-Back Group

    A teach-back lesson will be provided to physician participants (Teach-Back Group), who are participating in challenging clinical discussions with patients

    Other: Teach-Back Lesson

Interventions

  • OtherTeach-Back Lesson

    A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients

06

What researchers measure

Primary outcomes

  1. Provider's uninterrupted utterances

    We will assess this outcome directly from audio-recorded conversations. A coding scheme will then be developed that captures the average length of provider utterance without asking a question or an interruption from a patient

    Time frame: End of discussion with patient, 20 minutes

  2. Patient/provider talking ratio

    This outcome will also be assessed from audio-recorded conversations. The transcript will be coded and the coding scheme will compare how often and how long patients talk compared to provider talking.

    Time frame: End of discussion with patient, 20 minutes

Secondary outcomes

  1. Providers perceptions about teach-back

    This outcome will be assessed via semi-structured interviews.

    Time frame: End of semi-structured interview, one hour

  2. Providers belief of future use of teach-back

    This outcome will be assessed via the semi-structured interview

    Time frame: End of semi-structured interview, one hour

07

Study locations

1 site
  • Duke University Health System
    Durham, North Carolina 27710, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03058393
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 20, 2017
Start date
Apr 17, 2017
Primary completion
Nov 7, 2018
Completion
Nov 7, 2018
Last update
Dec 17, 2019

Study contacts

Richard C Mather III, MD, MBA
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion